Business
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or th
About this update from Nuvectis Pharma, Inc.
[{"type":"image","alt":"Nuvectis Pharma, Inc.","displaySize":"","headline":null,"caption":"Nuvectis Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":152,"url":"https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W.V.VnmdN5OtxNT977ZzKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d","width":300,"height":152}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategy","length":325,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed $15.5M financing, extending projected cash runway into 1Q2027","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":396,"olType":false},{"type":"text","content":"FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2025 and provided an update on recent business progress.","length":431,"tagName":"p"},{"type":"text","content":"Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “The start of 2025 has been eventful for us at Nuvectis as we continued to advance our two clinical programs.” Mr. Bentsur continued, “Last week we provided the first clinical data update for NXP900 from the Phase 1a dose escalation "all comers" study, demonstrating a robust pharmacodynamic response and acceptable safety profile in patients with advanced cancers. We are approaching the conclusion of this portion of the Phase 1 program and are completing our preparations for the Phase 1b portion, into which patients with cancers harboring specific genetic alterations will be enrolled to evaluate, for the first time, the therapeutic potential ...